Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 32Neoplasms 26Depression 21Fatigue 20Prostatic Neoplasms 13Lymphoma, Follicular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Multiple Myeloma 11Lymphoma, Large B-Cell, Diffuse 10Lung Neoplasms 10Colorectal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Pain 9Lymphoma, Non-Hodgkin 9Lymphoma, Mantle-Cell 9Lymphoma, Large-Cell, Immunoblastic 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hodgkin Disease 9Burkitt Lymphoma 9Anxiety Disorders 9Vomiting 7Nausea 7Leukemia, Myeloid, Acute 7Leukemia, Myeloid, Accelerated Phase 7Leukemia, Hairy Cell 7Head and Neck Neoplasms 7Carcinoma, Ovarian Epithelial 7Blast Crisis 7

Interventions

Therapeutics 1Surveys and Questionnaires 1Patient Reported Outcome Measures 1Ethanol 1Dosage Forms 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Substance-Related Disorders × Therapeutics × Clear all
NCT04345718 2025-12-09

EXHITENTRE

Hennepin Healthcare Research Institute

Phase 2/3 Completed
344 enrolled
Lymphoid

Lymphoma, Follicular, Opioid-Related Disorders, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡